Study of ASN51 in Adults With Early Alzheimer's Disease
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of ASN51 in Adults With Early Alzheimer's Disease
Sponsor: Asceneuron S.A.
Terminated
Strategic decision
Other terminated trials from Asceneuron S.A.
More terminations from Asceneuron S.A.
Other Alzheimer Disease trials with similar outcome
A PHASE2 clinical study on Alzheimer Disease, this trial is terminated or withdrawn. The trial is conducted by Asceneuron S.A. and has accumulated 5 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Jul 2025 — Present [monthly]
Terminated PHASE2
-
Apr 2025 — Jul 2025 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Feb 2025 — Apr 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE2
First recorded
Oct 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Asceneuron S.A.
For direct contact, visit the study record on ClinicalTrials.gov .